Rhiannon Morris

1.3k total citations · 1 hit paper
11 papers, 784 citations indexed

About

Rhiannon Morris is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Rhiannon Morris has authored 11 papers receiving a total of 784 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Rhiannon Morris's work include Cytokine Signaling Pathways and Interactions (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and interferon and immune responses (2 papers). Rhiannon Morris is often cited by papers focused on Cytokine Signaling Pathways and Interactions (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and interferon and immune responses (2 papers). Rhiannon Morris collaborates with scholars based in Australia, United Kingdom and Lebanon. Rhiannon Morris's co-authors include Nadia J. Kershaw, Jeffrey J. Babon, Elliott J. Stollar, Andrew C. Perkins, Artem Laktyushin, Andrew H. Wei, Hsin‐An Hou, Nicholas P. D. Liau, Shaun Fleming and Jarrod J. Sandow and has published in prestigious journals such as Nature Communications, Blood and Cancer Cell.

In The Last Decade

Rhiannon Morris

10 papers receiving 780 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The molecular details of cytokine signaling via the JAK/STAT pathway

2018 631 citations Rhiannon Morris, Nadia J. Kershaw et al. Protein Science profile →

Peers

Countries citing papers authored by Rhiannon Morris

Since Specialization

Citations

This map shows the geographic impact of Rhiannon Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhiannon Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhiannon Morris more than expected).

Fields of papers citing papers by Rhiannon Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rhiannon Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhiannon Morris. The network helps show where Rhiannon Morris may publish in the future.

Co-authorship network of co-authors of Rhiannon Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Rhiannon Morris. A scholar is included among the top collaborators of Rhiannon Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rhiannon Morris. Rhiannon Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Hashimoto's encephalitis - A case report 2024 ·Clinical Medicine ·(unknown), Rhiannon Morris, (unknown)	0
2	Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers 2024 ·Cancer Cell ·Sarah T. Diepstraten, Yuan Yin, (unknown), (unknown), Catherine Chang, (unknown), (unknown), (unknown), Giovanna Pomilio, Rhiannon Morris, Angela Georgiou, Véronique Litalien, Fiona C. Brown, Andrew W. Roberts, Andreas Strasser, Andrew H. Wei, Gemma L. Kelly	25
3	Structure guided studies of the interaction between PTP1B and JAK 2023 ·Communications Biology ·Rhiannon Morris, (unknown), (unknown), (unknown), Artem Laktyushin, (unknown), Nicholas P. D. Liau, Nicos A. Nicola, Tony Tiganis, Nadia J. Kershaw, Jeffrey J. Babon	5
4	TP53 status and impact on AML prognosis within the ELN 2022 risk classification 2023 ·Blood ·Shaun Fleming, Cheng‐Hong Tsai, Rhiannon Morris, Hsin‐An Hou, Andrew H. Wei	8
5	Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes 2022 ·International Journal of Molecular Sciences ·Casey T. Finnicum, Zahraa Rahal, Maya Hassane, Warapen Treekitkarnmongkol, Ansam Sinjab, Rhiannon Morris, (unknown), (unknown), (unknown), Jason L. Petersen, Philip L. Lorenzi, (unknown), Joseph F. Petrosino, Kristi L. Hoffman, Junya Fujimoto, Seyed Javad Moghaddam, Humam Kadara	7
6	Uncovering protein function: from classification to complexes 2022 ·Essays in Biochemistry ·Rhiannon Morris, (unknown), Elliott J. Stollar	71
7	Structural and functional analysis of target recognition by the lymphocyte adaptor protein LNK 2021 ·Nature Communications ·Rhiannon Morris, Yaoyuan Zhang, Julia I. Ellyard, Carola G. Vinuesa, James M. Murphy, Artem Laktyushin, Nadia J. Kershaw, Jeffrey J. Babon	6
8	Dissecting the molecular control of Interleukin 6 signaling using the M1 cell line 2021 ·Cytokine ·Rhiannon Morris, Douglas J. Hilton, Andrew Jarratt, Jeffrey J. Babon	2
9	The Role of LNK (SH2B3) in the Regulation of JAK-STAT Signalling in Haematopoiesis 2021 ·Pharmaceuticals ·Rhiannon Morris, (unknown), Andrew C. Perkins, Nadia J. Kershaw, Jeffrey J. Babon	18
10	Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1 2019 ·Cancers ·Nicholas P. D. Liau, Artem Laktyushin, Rhiannon Morris, Jarrod J. Sandow, Nicos A. Nicola, Nadia J. Kershaw, Jeffrey J. Babon	11
11	The molecular details of cytokine signaling via the JAK/STAT pathway breakdown → 2018 ·Protein Science ·Rhiannon Morris, Nadia J. Kershaw, Jeffrey J. Babon	631

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact